Adaptive Biotechnologies Corp (ADPT)vsThermo Fisher Scientific Inc (TMO)
ADPT
Adaptive Biotechnologies Corp
$24.20
-0.12%
HEALTHCARE · Cap: $3.90B
TMO
Thermo Fisher Scientific Inc
$609.82
+1.10%
HEALTHCARE · Cap: $225.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 14940% more annual revenue ($46.34B vs $308.08M). TMO leads profitability with a 15.0% profit margin vs -20.7%. TMO earns a higher WallStSmart Score of 60/100 (C+).
ADPT
Avoid28
out of 100
Grade: F
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.0%
Fair Value
$31.91
Current Price
$24.20
$7.71 discount
Margin of Safety
-76.7%
Fair Value
$345.06
Current Price
$609.82
$264.76 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.5% year-over-year
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
0.0% earnings growth
Trading at 26.9x book value
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : ADPT
The primary concerns for ADPT are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 2.87 is elevated, increasing financial risk.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ADPT profiles as a growth stock while TMO is a value play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.10 — expect wider price swings.
ADPT is growing revenue faster at 21.5% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
TMO scores higher overall (60/100 vs 28/100) and 10.5% revenue growth. ADPT offers better value entry with a 51.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?